A Phase 2, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety and Efficacy of RX-1741 Versus Linezolid in the Outpatient Treatment of Adult Patients With Uncomplicated Skin and Skin Structure Infection.

Trial Profile

A Phase 2, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety and Efficacy of RX-1741 Versus Linezolid in the Outpatient Treatment of Adult Patients With Uncomplicated Skin and Skin Structure Infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2014

At a glance

  • Drugs Radezolid (Primary) ; Linezolid
  • Indications Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections; Staphylococcal infections
  • Focus Therapeutic Use
  • Sponsors Melinta Therapeutics
  • Most Recent Events

    • 28 Oct 2008 Results were presented at ICAAC/IDSA 2008.
    • 21 Oct 2008 Results to be presented at ICAAC/IDSA 2008, according to a Rib-X media release.
    • 05 May 2008 Status change from recruiting to completed, according to clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top